HMD Biomedical, Inc.
TTPEX:666012.60
TWD
-0.10
(-0.79%)
ISIN
TW0006660004
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Hsinchu Taiwan
- Website
- hmdbio.com
- Similar Companies
- Business
- HMD BioMedical Inc. is a medical device and in vitro diagnostics manufacturer specializing in the research, development, production, and commercialization of biosensing technologies and blood glucose monitoring systems. Founded in 2000 and headquartered in Xinpu Township, Hsinchu County, Taiwan, the company operates within the biotechnology and medical instrumentation sectors, delivering self-monitoring of blood glucose (SMBG) and point-of-care testing (POCT) solutions for diabetic healthcare management and clinical monitoring. The company offers a comprehensive portfolio of diagnostic products and manufacturing services, which it markets under its proprietary GlucoLeader brand as well as through original equipment manufacturer (OEM), original design manufacturer (ODM), and private-label arrangements. Its core product lineup includes electrochemical blood glucose monitoring systems utilizing glucose oxidase (GOD) and flavin adenine dinucleotide glucose dehydrogenase (GDH-FAD) enzyme technologies; portable blood glucose meters featuring automatic coding, rapid test times, and micro-sample blood volume requirements, such as the GlucoLeader Enhance, GlucoLeader Enhance 2, and GlucoLeader GV01 series; specialized single-use electrochemical biosensor test strips; glucose control solutions for system calibration and quality assurance; adjustable lancing devices and sterile lancets; smart diabetes management systems equipped with Bluetooth wireless connectivity and data synchronization capabilities for mobile health tracking; and supplementary healthcare consumables, including antimicrobial diabetic protective socks and medical face masks. In addition to finished diagnostic devices, HMD BioMedical provides full-cycle OEM/ODM contract development services encompassing biosensor circuit design, reagent formulation, plastic tooling, automated strip assembly, and regulatory registration support. HMD BioMedical serves individual patients, hospitals, clinics, pharmacies, and international healthcare distributors across Taiwan, the Asia-Pacific region, Europe, and the Americas. The company maintains internationally certified manufacturing facilities compliant with ISO 13485, Medical Device Single Audit Program (MDSAP), CE Mark (IVDD/IVDR), Taiwan TFDA GMP/QMS, and U.S. FDA 510(k) quality and regulatory standards. In recent strategic developments, HMD BioMedical completed its public registration and commenced trading on the Emerging Stock Board of the Taipei Exchange (TPEx: 6660) in October 2026 to accelerate corporate capitalization. The company has simultaneously broadened its research and development pipeline toward next-generation connected digital health platforms, upgraded automated production lines for electrochemical strip manufacturing, and expanded global OEM/ODM strategic partnerships to address growing international demand for decentralized chronic disease monitoring.